SEC Form 4 · accession 0000886163-15-000021
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nishan M DeSilva
Officer — VP, Corporate Development
Period of report
Feb 10, 2015
Accepted (ET)
Feb 11, 2015 · 8:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 10, 2015 | S | 2,300 | $56.34 | D | 16,359 | D | |
| Common Stock | Feb 10, 2015 | A | 5,923 | $0.00 | A | 22,282 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $56.26 | Feb 10, 2015 | A | 20,873 | A | — | Feb 10, 2025 | Common Stock | 20,873 | 20,873 | D |
Explanation of responses
- F1Shares sold to cover taxes on the vesting of restricted stock.
- F2Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/10/15.